👉🏻 Vaccination: A Strategic Investment and Asset
Vaccines Europe has published its 2025 Annual Report against a backdrop of growing misinformation. The report highlights that its member companies currently have 91 vaccine and monoclonal antibody candidates in clinical development. The association also calls for lifelong immunization to be recognized as an investment and a strategic asset for Europe's economic stability.
👉🏻 Supplementary Protection Certificate Extension Divides the European Parliament
The proposal to extend Supplementary Protection Certificates (SPCs) by 12 months for eligible medicines has divided the European Parliament. Rapporteur Wouter Beke (EPP) supports a conditional extension linked to research and development and manufacturing activities in Europe. By contrast, Tiemo Wölken (S&D) and Ville Niinistö (Greens) oppose the proposal, arguing that there is insufficient evidence to justify it, that it would increase healthcare costs, and that it could delay the market entry of biosimilars.
👉🏻 New Bioproduction Hubs Are Emerging Across the United States
In the United States, new regions are emerging as alternatives to Greater Boston for the biomanufacturing industry, according to Biopharma Dive. Lancaster County, Pennsylvania, is experiencing rapid growth driven by investments in new vaccine manufacturing capacity. Oklahoma City, Oklahoma, is strengthening its position through an expanding network of contract development and manufacturing organizations (CDMOs), while Las Vegas, Nevada, is attracting companies with lower operating costs and the Roseman Bioventures incubator.